Reviewnpj drug discovery2026

Proportionate evidence in biosimilar development: when a comparative efficacy study can still change the regulatory conclusion.

Sarfaraz K NiaziPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.